Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 02.05.14 in Vol 16, No 5 (2014): May

This paper is in the following e-collection/theme issue:

Works citing "Monitoring of Internet Forums to Evaluate Reactions to the Introduction of Reformulated OxyContin to Deter Abuse"

Emily C McNaughton, Paul M Coplan, Ryan A Black, Sarah E Weber, Howard D Chilcoat, Stephen F Butler

J Med Internet Res 2014 (May 02); 16(5):e119 

According to Crossref, the following articles are citing this article (DOI 10.2196/jmir.3397):

(note that this is only a small subset of citations)

  1. Loeser KC, Rodriguez R. Regulatory and evidence-based considerations for abuse-deterrent opioids. American Journal of Health-System Pharmacy 2019;76(2):114
    CrossRef
  2. Coplan P, Chilcoat H, Butler S, Sellers E, Kadakia A, Harikrishnan V, Haddox J, Dart R. The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting. Clinical Pharmacology & Therapeutics 2016;100(3):275
    CrossRef
  3. Jones MR, Carney MJ, Kaye RJ, Prabhakar A, Kaye AD. Drug Formulation Advances in Extended-Release Medications for Pain Control. Current Pain and Headache Reports 2016;20(6)
    CrossRef
  4. Maincent J, Zhang F. Recent advances in abuse-deterrent technologies for the delivery of opioids. International Journal of Pharmaceutics 2016;510(1):57
    CrossRef
  5. Vosburg SK, Haynes C, Besharat A, Green JL. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction‐Related Surveillance (RADARS) System Web Monitoring Program. Pharmacoepidemiology and Drug Safety 2017;26(9):1044
    CrossRef
  6. Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties. Pain Medicine 2015;16(11):2142
    CrossRef
  7. Anderson L, Bell HG, Gilbert M, Davidson JE, Winter C, Barratt MJ, Win B, Painter JL, Menone C, Sayegh J, Dasgupta N. Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis. JMIR Public Health and Surveillance 2017;3(1):e6
    CrossRef
  8. Jones CM, Muhuri PK, Lurie PG. Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013. The Clinical Journal of Pain 2017;33(5):452
    CrossRef
  9. Webster LR, Pantaleon C, Iverson M, Smith MD, Kinzler ER, Aigner S. Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. Pain Research and Management 2018;2018:1
    CrossRef
  10. Chisholm-Burns MA, Spivey CA, Sherwin E, Wheeler J, Hohmeier K. The opioid crisis: Origins, trends, policies, and the roles of pharmacists. American Journal of Health-System Pharmacy 2019;76(7):424
    CrossRef
  11. Sarker A, DeRoos A, Perrone J. Mining social media for prescription medication abuse monitoring: a review and proposal for a data-centric framework. Journal of the American Medical Informatics Association 2020;27(2):315
    CrossRef
  12. R. Scott K, Nelson L, Meisel Z, Perrone J. Opportunities for Exploring and Reducing Prescription Drug Abuse Through Social Media. Journal of Addictive Diseases 2015;34(2-3):178
    CrossRef
  13. Severtson SG, Ellis MS, Kurtz SP, Rosenblum A, Cicero TJ, Parrino MW, Gilbert MK, Buttram ME, Dasgupta N, BucherBartelson B, Green JL, Dart RC. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug and Alcohol Dependence 2016;168:219
    CrossRef
  14. Peacock A, Degenhardt L, Hordern A, Larance B, Cama E, White N, Kihas I, Bruno R. Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation. International Journal of Drug Policy 2015;26(12):1265
    CrossRef
  15. Butler SF, McNaughton EC, Black RA, Cassidy TA. Evaluation of the Relative Abuse of an OROS Extended-release Hydromorphone HCI Product. The Clinical Journal of Pain 2018;34(7):618
    CrossRef
  16. Gasior M, Bond M, Malamut R. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgraduate Medicine 2016;128(1):85
    CrossRef
  17. Sellers EM, Shram MJ, Schoedel KA. The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond. Pharmaceutical Medicine 2014;28(6):317
    CrossRef
  18. Sarker A, O’Connor K, Ginn R, Scotch M, Smith K, Malone D, Gonzalez G. Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter. Drug Safety 2016;39(3):231
    CrossRef
  19. Brennan MJ, Kopecky EA, Marseilles A, O'Connor M, Fleming AB. The comparative pharmacokinetics of physical manipulation by crushing of Xtampza® ER compared with OxyContin®. Pain Management 2017;7(6):461
    CrossRef
  20. Litman RS, Pagán OH, Cicero TJ. Abuse-deterrent Opioid Formulations. Anesthesiology 2018;128(5):1015
    CrossRef
  21. Butler SF, Oyedele NK, Dailey Govoni T, Green JL. How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users. JMIR Public Health and Surveillance 2020;6(1):e16038
    CrossRef
  22. Harder VS, Varni SE, Murray KA, Plante TB, Villanti AC, Wolfson DL, Maruti S, Fairfield KM. Prescription opioid policies and associations with opioid overdose and related adverse effects. International Journal of Drug Policy 2021;97:103306
    CrossRef

According to Crossref, the following books are citing this article (DOI 10.2196/jmir.3397):

  1. Buller DB, Walkosz BJ, Gill Woodall W. Prevention of Substance Use. 2019. Chapter 20:319
    CrossRef
  2. McAninch J, Secora A, Kornegay C, Staffa J. Pharmacoepidemiology. 2019. :701
    CrossRef